Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

NCT07128381 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Myelofibrosis (MF)
Chronic Myelomonocytic Leukemia (CMML)

Interventions

DRUG: Axatilimab (SNDX-6352)
DRUG: Ruxolitinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]